Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Loss of microbial diversity and pathogen domination of the gut microbiota in critically ill patients.

Ravi A, Halstead FD, Bamford A, Casey A, Thomson NM, van Schaik W, Snelson C, Goulden R, Foster-Nyarko E, Savva GM, Whitehouse T, Pallen MJ, Oppenheim BA.

Microb Genom. 2019 Sep;5(9). doi: 10.1099/mgen.0.000293. Epub 2019 Sep 11.

2.

Gaps in communication between different staff groups and older adult patients foster unnecessary antibiotic prescribing for urinary tract infections in hospitals: a qualitative translation approach.

Saukko PM, Oppenheim BA, Cooper M, Rousham EK.

Antimicrob Resist Infect Control. 2019 Aug 5;8:130. doi: 10.1186/s13756-019-0587-2. eCollection 2019.

3.

The potential of visible blue light (405 nm) as a novel decontamination strategy for carbapenemase-producing enterobacteriaceae (CPE).

Halstead FD, Ahmed Z, Bishop JRB, Oppenheim BA.

Antimicrob Resist Infect Control. 2019 Jan 17;8:14. doi: 10.1186/s13756-019-0470-1. eCollection 2019.

4.

Whole genome sequencing of toxigenic Clostridium difficile in asymptomatic carriers: insights into possible role in transmission.

Halstead FD, Ravi A, Thomson N, Nuur M, Hughes K, Brailey M, Oppenheim BA.

J Hosp Infect. 2019 Jun;102(2):125-134. doi: 10.1016/j.jhin.2018.10.012. Epub 2018 Oct 22.

PMID:
30359648
5.

Use of an engineered honey to eradicate preformed biofilms of important wound pathogens: an in vitro study.

Halstead FD, Webber MA, Oppenheim BA.

J Wound Care. 2017 Aug 2;26(8):442-450. doi: 10.12968/jowc.2017.26.8.442.

PMID:
28795889
6.

A systematic review of quantitative burn wound microbiology in the management of burns patients.

Halstead FD, Lee KC, Kwei J, Dretzke J, Oppenheim BA, Moiemen NS.

Burns. 2018 Feb;44(1):39-56. doi: 10.1016/j.burns.2017.06.008. Epub 2017 Aug 4.

PMID:
28784345
7.

Antibacterial Activity of Blue Light against Nosocomial Wound Pathogens Growing Planktonically and as Mature Biofilms.

Halstead FD, Thwaite JE, Burt R, Laws TR, Raguse M, Moeller R, Webber MA, Oppenheim BA.

Appl Environ Microbiol. 2016 Jun 13;82(13):4006-4016. doi: 10.1128/AEM.00756-16. Print 2016 Jul 1.

8.

In vitro activity of an engineered honey, medical-grade honeys, and antimicrobial wound dressings against biofilm-producing clinical bacterial isolates.

Halstead FD, Webber MA, Rauf M, Burt R, Dryden M, Oppenheim BA.

J Wound Care. 2016 Feb;25(2):93-4, 96-102. doi: 10.12968/jowc.2016.25.2.93.

PMID:
26878302
9.

Protocol for a systematic review of quantitative burn wound microbiology in the management of burns patients.

Kwei J, Halstead FD, Dretzke J, Oppenheim BA, Moiemen NS.

Syst Rev. 2015 Nov 6;4:150. doi: 10.1186/s13643-015-0137-9.

10.

The Antibacterial Activity of Acetic Acid against Biofilm-Producing Pathogens of Relevance to Burns Patients.

Halstead FD, Rauf M, Moiemen NS, Bamford A, Wearn CM, Fraise AP, Lund PA, Oppenheim BA, Webber MA.

PLoS One. 2015 Sep 9;10(9):e0136190. doi: 10.1371/journal.pone.0136190. eCollection 2015.

11.

Emergence of linezolid resistance in hepatobiliary infections caused by Enterococcus faecium.

Niebel M, Perera MT, Shah T, Marudanayagam R, Martin K, Oppenheim BA, David MD.

Liver Transpl. 2016 Feb;22(2):201-8. doi: 10.1002/lt.24328.

12.

Antimicrobial dressings: Comparison of the ability of a panel of dressings to prevent biofilm formation by key burn wound pathogens.

Halstead FD, Rauf M, Bamford A, Wearn CM, Bishop JRB, Burt R, Fraise AP, Moiemen NS, Oppenheim BA, Webber MA.

Burns. 2015 Dec;41(8):1683-1694. doi: 10.1016/j.burns.2015.06.005. Epub 2015 Jul 16.

PMID:
26188884
13.

A multi-centre comparison of nursing staff time required for the preparation and administration of liposomal amphotericin B and amphotericin B deoxycholate vs. voriconazole.

Flynn E, Marciniak A, Barbabietola G, Oppenheim BA, Roberts C, Barker K.

J Clin Nurs. 2009 Apr;18(8):1168-79. doi: 10.1111/j.1365-2702.2008.02512.x. Epub 2008 Nov 12.

PMID:
19017372
14.

Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.

Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ.

Clin Microbiol Infect. 2008 Apr;14(4):307-14. doi: 10.1111/j.1469-0691.2007.01943.x. Epub 2008 Feb 2.

15.

Rapid recontamination with MRSA of the environment of an intensive care unit after decontamination with hydrogen peroxide vapour.

Hardy KJ, Gossain S, Henderson N, Drugan C, Oppenheim BA, Gao F, Hawkey PM.

J Hosp Infect. 2007 Aug;66(4):360-8. Epub 2007 Jul 25.

PMID:
17655975
16.

A study of the relationship between environmental contamination with methicillin-resistant Staphylococcus aureus (MRSA) and patients' acquisition of MRSA.

Hardy KJ, Oppenheim BA, Gossain S, Gao F, Hawkey PM.

Infect Control Hosp Epidemiol. 2006 Feb;27(2):127-32. Epub 2006 Feb 8.

PMID:
16465628
17.
18.

Distribution and characterization of staphylococcal interspersed repeat units (SIRUs) and potential use for strain differentiation.

Hardy KJ, Ussery DW, Oppenheim BA, Hawkey PM.

Microbiology. 2004 Dec;150(Pt 12):4045-52.

PMID:
15583157
19.

Methicillin resistant Staphylococcus aureus in the critically ill.

Hardy KJ, Hawkey PM, Gao F, Oppenheim BA.

Br J Anaesth. 2004 Jan;92(1):121-30. Review.

20.

Surveillance of antibiotic resistance in urinary tract infections--are we misleading prescribers?

Oppenheim BA.

Commun Dis Public Health. 2002 Sep;5(3):181-2. No abstract available.

PMID:
12434686
21.

Getting ahead of the curve: a new strategy for infectious diseases.

Oppenheim BA.

Hosp Med. 2002 Jul;63(7):390-1. No abstract available.

PMID:
12187596
22.

Rapid identification of candida species by TaqMan PCR.

Guiver M, Levi K, Oppenheim BA.

J Clin Pathol. 2001 May;54(5):362-6.

24.

Management of febrile neutropenia in low risk cancer patients.

Oppenheim BA, Anderson H.

Thorax. 2000 Aug;55 Suppl 1:S63-9. Review. No abstract available.

25.

Optimal management of central venous catheter-related infections--what is the evidence?

Oppenheim BA.

J Infect. 2000 Jan;40(1):26-30. Review. No abstract available.

PMID:
10762108
26.

Early investigation and initiation of therapy for invasive pulmonary aspergillosis in leukaemic and bone marrow transplant patients.

Barnes AJ, Oppenheim BA, Chang J, Morgenstern GR, Scarffe JH.

Mycoses. 1999;42(5-6):403-8.

PMID:
10536432
27.

Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens.

Taylor ME, Oppenheim BA, Chadwick PR, Weston D, Palepou MF, Woodford N, Bellis M.

J Hosp Infect. 1999 Sep;43(1):25-32.

PMID:
10462636
28.

Endotoxin in blood and tissue in the sudden infant death syndrome.

Crawley BA, Morris JA, Drucker DB, Barson AJ, Morris J, Knox WF, Oppenheim BA.

FEMS Immunol Med Microbiol. 1999 Aug 1;25(1-2):131-5.

29.

Effect of time post mortem on the concentration of endotoxin in rat organs: implications for sudden infant death syndrome (SIDS).

Sayers NM, Crawley BA, Humphries K, Drucker DB, Oppenheim BA, Hunt LP, Morris JA, Telford DR.

FEMS Immunol Med Microbiol. 1999 Aug 1;25(1-2):125-30.

31.

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, Mufti GJ.

Bone Marrow Transplant. 1999 Jan;23(2):163-8.

33.

Improved recognition of MRSA case clusters by the application of molecular subtyping using pulsed-field gel electrophoresis.

Macfarlane L, Walker J, Borrow R, Oppenheim BA, Fox AJ.

J Hosp Infect. 1999 Jan;41(1):29-37.

PMID:
9949962
34.

PCR-ELISA for the early diagnosis of invasive pulmonary aspergillus infection in neutropenic patients.

Jones ME, Fox AJ, Barnes AJ, Oppenheim BA, Balagopal P, Morgenstern GR, Scarffe JH.

J Clin Pathol. 1998 Sep;51(9):652-6.

35.
36.

The changing pattern of infection in neutropenic patients.

Oppenheim BA.

J Antimicrob Chemother. 1998 Jun;41 Suppl D:7-11. Review.

PMID:
9688447
37.

Molecular characterisation of methicillin resistant Staphylococcus aureus.

Walker J, Fox AJ, Borrow R, Oppenheim BA.

Commun Dis Public Health. 1998 Jun;1(2):126-7.

PMID:
9644127
38.

Hospital-acquired infection in elderly patients.

Taylor ME, Oppenheim BA.

J Hosp Infect. 1998 Apr;38(4):245-60. Review.

PMID:
9602974
39.

Screening for bacterial vaginosis: a novel application of artificial nose technology.

Chandiok S, Crawley BA, Oppenheim BA, Chadwick PR, Higgins S, Persaud KC.

J Clin Pathol. 1997 Sep;50(9):790-1.

40.

Monitoring wound healing by odour.

Greenwood JE, Crawley BA, Clark SL, Chadwick PR, Ellison DA, Oppenheim BA, McCollum CN.

J Wound Care. 1997 May;6(5):219-21.

PMID:
9256726
41.

Endotoxin antibodies in African sleeping sickness.

Pentreath VW, Alafiatayo RA, Barclay GR, Crawley B, Doua F, Oppenheim BA.

Parasitology. 1997 Apr;114 ( Pt 4):361-5.

PMID:
9107022
42.

Controlling glycopeptide-resistant enterococci.

Chadwick PR, Oppenheim BA.

Clin Microbiol Infect. 1997 Feb;3(1):7-11. No abstract available.

43.

Comparison of agar-based media for primary isolation of glycopeptide-resistant enterococci.

Chadwick PR, Brown DF, Wilcox MH, Collyns TA, Walpole E, Dillon J, Smith R, Gopal Rao G, Oppenheim BA.

Clin Microbiol Infect. 1997;3(5):559-563.

44.

Antibiotic resistance in Neisseria meningitidis.

Oppenheim BA.

Clin Infect Dis. 1997 Jan;24 Suppl 1:S98-101. Review.

PMID:
8994787
45.

Glycopeptide-resistant enterococci isolated from uncooked meat.

Chadwick PR, Woodford N, Kaczmarski EB, Gray S, Barrell RA, Oppenheim BA.

J Antimicrob Chemother. 1996 Nov;38(5):908-9. No abstract available.

PMID:
8961065
46.

Epidemiology of an outbreak due to glycopeptide-resistant Enterococcus faecium on a leukaemia unit.

Chadwick PR, Oppenheim BA, Fox A, Woodford N, Morgenstern GR, Scarffe JH.

J Hosp Infect. 1996 Nov;34(3):171-82.

PMID:
8923271
47.

Review of clinical activity by microbiologists.

Chadwick PR, Barnes A, Oppenheim BA.

J Clin Pathol. 1996 Sep;49(9):780. No abstract available.

48.

Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis.

Barnes AJ, Wardley AM, Oppenheim BA, Morgenstern GR, Scarffe JH, Warnock DW, Johnson EM.

J Infect. 1996 Jul;33(1):43-5.

PMID:
8842994
49.

Cleaning as a cost-effective method of infection control.

Chadwick C, Oppenheim BA.

Lancet. 1996 Jun 22;347(9017):1776. No abstract available.

PMID:
8656946
50.

Report of a meeting on the epidemiology and control of glycopeptide-resistant enterococci.

Chadwick PR, Chadwick CD, Oppenheim BA.

J Hosp Infect. 1996 Jun;33(2):83-92. No abstract available.

PMID:
8808742

Supplemental Content

Loading ...
Support Center